Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration

Ítems similars

• Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
  per: Hilal, Talal, et al.
  Publicat: (2020)
• Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018
  per: DeMartino, Patrick C., et al.
  Publicat: (2020)
• An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
  per: Chen, Emerson Y., et al.
  Publicat: (2019)
• Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration’s Approval of Oncology Drugs
  per: Kim, Chul, et al.
  Publicat: (2016)
• Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration
  per: Martell, Robert E., et al.
  Publicat: (2013)